← Zhuhai Rundu Pharmaceutical overview

Zhuhai Rundu Pharmaceutical vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923.CS)

Q3 2026
▲2▼1

Rundu swings to profit as new heart drugs win approvals

  • New hypertension drug approvals widen product line Rundu won Chinese approval for azilsartan tablets and, separately, marketing approval for amlodipine besylate, the key ingredient in a common blood-pressure medicine. Both add to its heart and stroke product range, supporting future sales and its ingredient-to-finished-pill chain.

    These regulatory approvals are genuinely new and expand the products the company can sell.

  • Innovative heart-imaging drug gets provincial support Rundu's first-in-class higenamine hydrochloride injection was picked for Guangdong's innovative drug catalog. That status brings provincial policy support for promoting and selling the product, which should help it reach more hospitals and patients over time.

    This is a new regulatory win that could lift sales of a high-value innovative product.

  • Controlling shareholder still heavily pledged Controlling shareholder Li Xi released 2.15 million pledged shares, but 97.2% of his stake remains pledged. Heavy pledging can signal personal financial strain and, if shares fall, risks forced selling that would weigh on the stock price.

    This is the main counterweight to the good news and a real risk investors should weigh.

August 2026
▲2▼1

Rundu swings to profit as new heart drugs win approvals

  • New hypertension drug approvals widen product line Rundu won Chinese approval for azilsartan tablets and, separately, marketing approval for amlodipine besylate, the key ingredient in a common blood-pressure medicine. Both add to its heart and stroke product range, supporting future sales and its ingredient-to-finished-pill chain.

    These regulatory approvals are genuinely new and expand the products the company can sell.

  • Innovative heart-imaging drug gets provincial support Rundu's first-in-class higenamine hydrochloride injection was picked for Guangdong's innovative drug catalog. That status brings provincial policy support for promoting and selling the product, which should help it reach more hospitals and patients over time.

    This is a new regulatory win that could lift sales of a high-value innovative product.

  • Controlling shareholder still heavily pledged Controlling shareholder Li Xi released 2.15 million pledged shares, but 97.2% of his stake remains pledged. Heavy pledging can signal personal financial strain and, if shares fall, risks forced selling that would weigh on the stock price.

    This is the main counterweight to the good news and a real risk investors should weigh.

Latest
▲2▼1

Rundu swings to profit as new heart drugs win approvals

  • New hypertension drug approvals widen product line Rundu won Chinese approval for azilsartan tablets and, separately, marketing approval for amlodipine besylate, the key ingredient in a common blood-pressure medicine. Both add to its heart and stroke product range, supporting future sales and its ingredient-to-finished-pill chain.

    These regulatory approvals are genuinely new and expand the products the company can sell.

  • Innovative heart-imaging drug gets provincial support Rundu's first-in-class higenamine hydrochloride injection was picked for Guangdong's innovative drug catalog. That status brings provincial policy support for promoting and selling the product, which should help it reach more hospitals and patients over time.

    This is a new regulatory win that could lift sales of a high-value innovative product.

  • Controlling shareholder still heavily pledged Controlling shareholder Li Xi released 2.15 million pledged shares, but 97.2% of his stake remains pledged. Heavy pledging can signal personal financial strain and, if shares fall, risks forced selling that would weigh on the stock price.

    This is the main counterweight to the good news and a real risk investors should weigh.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.